U.S. markets open in 8 hours 41 minutes

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
18.24+0.30 (+1.67%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range18.12 - 18.27
52 Week Range12.55 - 21.59
Avg. Volume613,853
Market Cap72.861B
Beta (5Y Monthly)1.30
PE Ratio (TTM)9.89
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.76 (4.25%)
Ex-Dividend DateApr 29, 2020
1y Target Est22.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    Elanco to divest brands, forgo Canadian rights for Bayer's unit deal

    Elanco Animal Health Inc has decided against acquiring Bayer AG's Canadian distribution rights to several poultry insecticides, Canada's Competition Bureau said on Tuesday, as it looks to complete a $7.6-billion deal. The U.S.-based company will also divest its canine ear infection treatment product Osurnia and Bayer's feline dewormer Profender to address competition concerns about its acquisition of the German firm's veterinary drugs unit. The Competition Bureau said Elanco and Bayer's animal health unit were each other's closest rivals in several Canadian markets and a potential combination would result in a substantial decrease in competition.

  • Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

    Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

    Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.

  • Bayer puts Roundup future claims settlement on hold

    Bayer puts Roundup future claims settlement on hold

    Bayer <BAYGn.DE> was forced on Wednesday to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims. The German company said that lawyers representing those preparing a class action had withdrawn a request for court approval of the $1.25 billion future claims scheme, part of a broader $10.9 billion agreement to settle close to 100,000 U.S. lawsuits related to Roundup. The move would give both sides more time to address questions raised by Federal District Court Judge Vince Chhabria of the Northern District of California who presides over the federal Roundup litigation, Bayer said.